NCT02850484View on ClinicalTrials.gov

A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block

PHASE1CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
AsthmaChronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Budesonide

Inhaled corticosteroid

DRUG

Formoterol

Long Acting Beta Agonist (LABA)

Sponsors
All Listed Sponsors
lead

Intech Biopharm Ltd.

INDUSTRY

NCT02850484 - A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block | Biotech Hunter | Biotech Hunter